Skip to main content
Equibles
UFPT logo

UFPT · Ufp Technologies Inc · Documents

Track UFPT — free

Use UFPT with AI

Add company filings, earnings and prices to ChatGPT or Claude, then ask questions in your own chat.

Choose your app for step-by-step connection instructions. Sign in with Equibles when asked; no code or API key is needed.

Claude ChatGPT

After connecting, ask your AI to use Equibles to research UFPT.

Other apps & server URL
https://mcp.equibles.com/mcp
Gemini CLI setup
or ask here

Free, nothing to set up — ALVIS runs on the same tools and cites every figure.

See what you can ask in ChatGPT or Claude

All connection guides →
$311.78 +8.31 (+2.74%) Play latest call Q3 2026 earnings call transcript
S&P 600 member Russell 2000 member Rebalance outlook locked
Market Cap
$2.35B
Shares
7.75M
Volume · Nov 9 12.76K Avg daily vol (3M) 119.3K

The company's filings, earnings calls and investor events, most recent first. Search and read these filings from Claude or ChatGPT with the SEC filings MCP server →

Annual report FY2025 Revenue $602.8M up 19.5% 10-K filed Feb 27, 2026 Quarterly report New FY2026 Q3 Revenue $172.43M up 11.6% 10-Q filed Nov 6, 2026 Latest results New Q3 net income rises 25.8% on $172.4 million sales 8-K filed Nov 3, 2026 Earnings call New Q3 2026 earnings call Held Nov 4, 2026
2026
Nov 6
Quarterly report 10-Q FY2026 Q3, ended Sep 30
Sales rise 10.3% as gross margin reaches 29.2%

UFP Technologies reported net sales of $500.6 million for the nine months ended September 30, 2026, up 10.3%, and gross margin of 29.2% versus 28.3%. It closed the CI Medical acquisition in the third quarter of 2026.

Revenue $172.43M ▲ 11.6% Net income $20.62M ▲ 25.8% Diluted EPS $2.64 ▲ 25.1%
Read from the MD&A section
3 source passages
Net sales for the nine months ended September 30, 2026 increased 10.3% to $500.6 million from $453.9 million in the same period last year. Gross Margin increased to 29.2% for the nine months ended September 30, 2026, from 28.3% for the same period in 2025, driven primarily by increased operating efficiencies as well as leveraging strong organic sales growth against fixed overhead costs. The Company closed on the acquisition of CI Medical in the third quarter of 2026. Open the document at this passage
Nov 4
Earnings call
Third-quarter sales rise 11.6%, adjusted EPS reaches $2.88

UFP Technologies reported third-quarter sales of $172.4 million, up 11.6%, organic growth of 11.1%, and adjusted EPS of $2.88. Management remained comfortable with 6% to 9% organic growth and 12 to 18 combined organic and inorganic growth.

6 source passages
welcome to UFP Technologies 3rd Quarter 2026 on e-Conference Call. Third quarter sales were $172.4 million, up 11.6%. Organic growth was 11.1%. Adjusted earnings per share increased to $2.88. I think we're comfortable with the 6% to 9%. I think we're comfortable with the organic growth range and then the overall 12 to 18 with regard to organic and inorganic growth combined. Open the document at this passage
Nov 3
Current report 8-K
Q3 net income rises 25.8% on $172.4 million sales

UFP Technologies reported Q3 net income of $20.6 million, up 25.8%, on sales of $172.4 million, up 11.6%, for the quarter ended September 30, 2026. GAAP diluted EPS was $2.64, and gross margin reached 29.4%.

Financial results
4 source passages
UFP Technologies, Inc. (Nasdaq: UFPT), a trusted contract development and manufacturing organization specializing in comprehensive solutions for medical devices, sterile packaging and other highly engineered custom products, today reported net income of $20.6 million for its third quarter ended September 30, 2026, 25.8% higher than net income of $16.4 million for the third quarter of 2025. Net sales for the quarter ended September 30, 2026 were $172.4 million, 11.6% higher than 2025 third quarter sales of $154.6 million. Generally accepted accounting principles ("GAAP") and adjusted earnings per diluted common share outstanding ("EPS") for the quarter ended September 30, 2026 were $2.64 and $2.88, respectively. In the third quarter, sales grew 11.6%, including 11.1% organic growth, gross margins increased to 29.4%, and adjusted operating income grew 14.5%. Open the document at this passage
Aug 6
Quarterly report 10-Q FY2026 Q2, ended Jun 30
Quarterly report for FY2026 Q2 AI summary on its way
Revenue $173.96M ▲ 15.1% Net income $20.85M ▲ 21.4% Diluted EPS $2.68 ▲ 21.3%
May 8
Quarterly report 10-Q FY2026 Q1, ended Mar 31
Quarterly report for FY2026 Q1 AI summary on its way
Revenue $154.2M ▲ 4.1% Net income $17.5M ▲ 1.8% Diluted EPS $2.24 ▲ 1.4%
Apr 30
Proxy statement DEF 14A Meeting Jun 4, 2026
Proxy statement AI summary on its way
Feb 27
Annual report 10-K FY2025, ended Dec 31
Annual report for FY2025 AI summary on its way
Revenue $602.8M ▲ 19.5% Net income $68.31M ▲ 15.8% Diluted EPS $8.75 ▲ 15.4%
2025
Nov 7
Quarterly report 10-Q FY2025 Q3, ended Sep 30
Quarterly report for FY2025 Q3
Revenue $154.56M ▲ 6.5% Net income $16.38M ▲ 0.1% Diluted EPS $2.11 ▲ unchanged
Aug 11
Quarterly report 10-Q FY2025 Q2, ended Jun 30
Quarterly report for FY2025 Q2
Revenue $151.18M ▲ 37.2% Net income $17.18M ▲ 26.8% Diluted EPS $2.21 ▲ 26.3%
May 12
Quarterly report 10-Q FY2025 Q1, ended Mar 31
Quarterly report for FY2025 Q1
Revenue $148.15M ▲ 41.1% Net income $17.18M ▲ 35.4% Diluted EPS $2.21 ▲ 34.8%
Mar 3
Annual report 10-K FY2024, ended Dec 31
Annual report for FY2024
Revenue $504.42M ▲ 26.1% Net income $58.98M ▲ 31.3% Diluted EPS $7.58 ▲ 30.0%
2024
Nov 12
Quarterly report 10-Q FY2024 Q3, ended Sep 30
Quarterly report for FY2024 Q3
Revenue $145.17M ▲ 44.0% Net income $16.36M ▲ 39.9% Diluted EPS $2.11 ▲ 38.8%
Aug 9
Quarterly report 10-Q FY2024 Q2, ended Jun 30
Quarterly report for FY2024 Q2
Revenue $110.18M ▲ 10.1% Net income $13.55M ▲ 14.0% Diluted EPS $1.75 ▲ 12.9%
Showing 1–50 of 135 documents
Key facts CIK 914156 CUSIP 902673102 13F (30d) 167 filings 137 filers Visit website Investor relations